Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone650-837-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$853.83 million
Profitability
Miscellaneous
Employees484
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Wednesday, July, 31st. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.23 by $0.02. The biotechnology company earned $240.28 million during the quarter, compared to analyst estimates of $226.97 million. Exelixis had a return on equity of 31.31% and a net margin of 70.52%. Exelixis's quarterly revenue was up 29.1% compared to the same quarter last year. During the same period last year, the company earned $0.31 EPS. View Exelixis' Earnings History.
When is Exelixis' next earnings date?
What price target have analysts set for EXEL?
6 brokers have issued 12 month price targets for Exelixis' stock. Their predictions range from $23.00 to $48.00. On average, they expect Exelixis' share price to reach $29.50 in the next twelve months. This suggests a possible upside of 52.3% from the stock's current price. View Analyst Price Targets for Exelixis.
What is the consensus analysts' recommendation for Exelixis?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.
Has Exelixis been receiving favorable news coverage?
Headlines about EXEL stock have been trending negative recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Exelixis earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Exelixis.
Are investors shorting Exelixis?
Exelixis saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 15,101,400 shares, an increase of 7.1% from the July 31st total of 14,104,400 shares. Based on an average daily volume of 2,560,000 shares, the days-to-cover ratio is presently 5.9 days. Currently, 5.2% of the shares of the stock are sold short. View Exelixis' Current Options Chain.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX) and Luna Innovations (LUNA).
What other stocks do shareholders of Exelixis own?
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
- Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
- Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
- Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)
Who are Exelixis' major shareholders?
Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.13%), BlackRock Inc. (10.13%), Vanguard Group Inc. (9.17%), Meditor Group Ltd (4.97%), AQR Capital Management LLC (4.52%) and Renaissance Technologies LLC (4.44%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Which major investors are selling Exelixis stock?
EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., Invesco Ltd., Canada Pension Plan Investment Board, Morgan Stanley, BlackRock Inc. and BlackRock Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Which major investors are buying Exelixis stock?
EXEL stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, Prudential Financial Inc., Fiera Capital Corp, Marshall Wace LLP and First Trust Advisors LP. View Insider Buying and Selling for Exelixis.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $19.37.
How big of a company is Exelixis?
Exelixis has a market capitalization of $5.87 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.
What is Exelixis' official website?
How can I contact Exelixis?
Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
